secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2026-10-05T12:05:26+00:00
Accession:  0001104659-26-113506
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

TELA Bio wins FDA 510(k) clearance for Liora fully resorbable surgical mesh
---------------------------------------------------------------------------

- FDA granted 510(k) clearance for Liora Monofilament Scaffold, a fully resorbable synthetic surgical mesh for soft tissue reinforcement.
- Liora is the first implant fully developed in TELA Bio's ISO 8 certified cleanroom in Malvern, PA, and the first fully resorbable synthetic product in its portfolio.
- CEO Heather Getz called the clearance 'a significant milestone' that expands options for surgeons and patients in soft tissue reconstruction.
- Company says Liora expands its footprint in the soft tissue reconstruction market; more details to come on the Q3 earnings call expected in early November.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926113506/0001104659-26-113506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926113506/tm2627013d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-113506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer